Search Results - "Hamann, Philip R."

Selection of Reaction Additives Used in the Preparation of Monomeric Antibody−Calicheamicin Conjugates by Hollander, Irwin, Kunz, Arthur, Hamann, Philip. R

“…The formation of protein aggregates can be a major problem during the preparation of antibody−drug conjugates. Herein is described the methods by which…”
Get full text

Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia by Hamann, Philip R, Hinman, Lois M, Hollander, Irwin, Beyer, Carl F, Lindh, Delores, Holcomb, Ryan, Hallett, William, Tsou, Hwei-Ru, Upeslacis, Janis, Shochat, Dan, Mountain, Andrew, Flowers, David A, Bernstein, Irwin

“…CD33 is expressed by acute myeloid leukemia (AML) cells in >80% of patients but not by normal hematopoietic stem cells, suggesting that elimination of CD33+…”
Get full text

Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma by DIJOSEPH, John F, DOUGHER, Maureen M, KALYANDRUG, Lyka B, ARMELLINO, Douglas C, BOGHAERT, Erwin R, HAMANN, Philip R, MORAN, Justin K, DAMLE, Nitin K

“…Purpose: CMC-544 is a CD22-targeted cytotoxic immunoconjugate, currently being evaluated in B-cell non-Hodgkin's lymphoma (B-NHL) patients. Rituximab is a…”
Get full text

Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma by DIJOSEPH, John F, GOAD, Mary E, DOUGHER, Maureen M, BOGHAERT, Erwin R, KUNZ, Arthur, HAMANN, Philip R, DAMLE, Nitin K

“…Purpose: CMC-544 is a CD22-targeted immunoconjugate of calicheamicin and exerts a potent cytotoxic effect against CD22 + B-cell lymphoma. This study evaluated…”
Get full text

CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab by Dijoseph, John F, Dougher, Maureen M, Armellino, Douglas C, Kalyandrug, Lyka, Kunz, Arthur, Boghaert, Erwin R, Hamann, Philip R, Damle, Nitin K

“…Tumor-targeted delivery of a potent cytotoxic agent, calicheamicin, using its immunoconjugates is a clinically validated therapeutic strategy. Rituximab is a…”
Get full text

Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22 by DIJOSEPH, John F, POPPLEWELL, Andrew, ZINKEWICH-PEOTTI, Karen, STEPHENS, Sue, WEIR, Neil, DAMLE, Nitin K, TICKLE, Simon, LADYMAN, Heather, LAWSON, Alastair, KUNZ, Arthur, KHANDKE, Kiran, ARMELLINO, Douglas C, BOGHAERT, Erwin R, HAMANN, Philip R

“…Antibody-targeted chemotherapy with immunoconjugates of calicheamicin is a clinically validated strategy in cancer therapy. This study describes the selection…”
Get full text

Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles by Wissner, Allan, Hamann, Philip R., Nilakantan, Ramaswamy, Greenberger, Lee M., Ye, Fei, Rapuano, Timothy A., Loganzo, Frank

“…The syntheses and EGFR kinase inhibitory activity of a series of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles are described. Both…”
Get full text

Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells by DAMELIN, Marc, GELES, Kenneth G, BEHRENS, Carmen, CHOE, Sung E, RIOS, Carol, GRUZAS, Janet, SRIDHARAN, Latha, DOUGHER, Maureen, KUNZ, Arthur, HAMANN, Philip R, EVANS, Deborah, ARMELLINO, Douglas, FOLLETTIE, Maximillian T, KHANDKE, Kiran, MARQUETTE, Kimberly, TCHISTIAKOVA, Lioudmila, BOGHAERT, Erwin R, ABRAHAM, Robert T, WISTUBA, Ignacio I, ZHOU, Bin-Bing S, PING YUAN, BAXTER, Michelle, GOLAS, Jonathon, DIJOSEPH, John F, KARNOUB, Maha, SHUGUANG HUANG, DIESL, Veronica

“…Poorly differentiated tumors in non-small cell lung cancer (NSCLC) have been associated with shorter patient survival and shorter time to recurrence following…”
Get full text

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies by DiJoseph, John F., Armellino, Douglas C., Boghaert, Erwin R., Khandke, Kiran, Dougher, Maureen M., Sridharan, Latha, Kunz, Arthur, Hamann, Philip R., Gorovits, Boris, Udata, Chandrasekhar, Moran, Justin K., Popplewell, Andrew G., Stephens, Sue, Frost, Philip, Damle, Nitin K.

“…Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoconjugate of N-acetyl-γ-calicheamicin dimethyl hydrazide [CalichDMH],…”
Get full text

An Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia. Choice of Linker by Hamann, Philip R, Hinman, Lois M, Beyer, Carl F, Lindh, Delores, Upeslacis, Janis, Flowers, David A, Bernstein, Irwin

“…The anti-CD33 antibody, P67.6, has been chosen to target the potently cytotoxic calicheamicin antitumor antibiotics to acute myeloid leukemia (AML) due to the…”
Get full text

Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples by Boghaert, Erwin R., Khandke, Kiran M., Sridharan, Latha, Dougher, Maureen, DiJoseph, John F., Kunz, Arthur, Hamann, Philip R., Moran, Justin, Chaudhary, Inder, Damle, Nitin K.

“…Purpose The present study aims to establish a method that provides fast, precise and reproducible pharmacokinetic (PK) parameters of antibody-calicheamicin…”
Get full text

Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193-N-Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-Positive Human Carcinoma Cells and Xenografts by BOGHAERT, Erwin R, SRIDHARAN, Latha, FROST, Philip, DAMLE, Nitin K, ARMELLINO, Douglas C, KHANDKE, Kiran M, DIJOSEPH, John F, KUNZ, Arthur, DOUGHER, Maureen M, JIANG, Fan, KALYANDRUG, Lyka B, HAMANN, Philip R

“…Purpose: Linking a cytotoxic anticancer drug to an antibody that recognizes a tumor-associated antigen can improve the therapeutic index of the drug. We asked…”
Get full text

Calicheamicin Derivatives Conjugated to Monoclonal Antibodies:  Determination of Loading Values and Distributions by Infrared and UV Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry and Electrospray Ionization Mass Spectrometry by Siegel, Marshall M, Tabei, Keiko, Kunz, Arthur, Hollander, Irwin J, Hamann, Philip R, Bell, Duncan H, Berkenkamp, Stefan, Hillenkamp, Franz

“…Calicheamicin derivatives (MW ∼1500) and monoclonal antibodies (MoAbs) conjugated to calicheamicin derivatives (MW ∼150 000) were analyzed by UV-MALDI/MS,…”
Get full text

An Anti-MUC1 Antibody−Calicheamicin Conjugate for Treatment of Solid Tumors. Choice of Linker and Overcoming Drug Resistance by Hamann, Philip R, Hinman, Lois M, Beyer, Carl F, Greenberger, Lee M, Lin, Clara, Lindh, Delores, Menendez, Ana T, Wallace, Rosalyn, Durr, Frederick E, Upeslacis, Janis

“…The anti-MUC1 antibody, CTM01, has been chosen to target the potently cytotoxic calicheamicin antitumor antibiotics to solid tumors of epithelial origin that…”
Get full text

A Calicheamicin Conjugate with a Fully Humanized Anti-MUC1 Antibody Shows Potent Antitumor Effects in Breast and Ovarian Tumor Xenografts by Hamann, Philip R, Hinman, Lois M, Beyer, Carl F, Lindh, Delores, Upeslacis, Janis, Shochat, Dan, Mountain, Andrew

“…Murine CTM01 is an internalizing murine IgG1 monoclonal antibody that recognizes the MUC1 antigen expressed on many solid tumors of epithelial origin…”
Get full text

Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy by BOGHAERT, Erwin R, KHANDKE, Kiran, DISCAFANI, Carolyn, DAMLE, Nitin K, SRIDHARAN, Latha, ARMELLINO, Douglas, DOUGHER, Maureen, DIJOSEPH, John F, KUNZ, Arthur, HAMANN, Philip R, SRIDHARAN, Ashwin, JONES, Stanley

“…Calicheamicin is a potent chemotherapeutic with a low therapeutic index that requires targeting to tumor cells for its use in the clinic. To treat acute…”
Get full text

Matrix-assisted UV-laser desorption/ionization mass spectrometric analysis of monoclonal antibodies for the determination of carbohydrate, conjugated chelator, and conjugated drug content by Siegel, Marshall M, Hollander, Irwin J, Hamann, Philip R, James, John P, Hinman, Lois, Smith, Bryan J, Farnsworth, Andrew P. H, Phipps, Alison, King, David J, et al, .

“…The chemically averaged molecular weights of a variety of native and conjugated monoclonal antibodies, approximately 150,000, were measured by matrix-assisted…”
Get full text

B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model by Dunussi-Joannopoulos, Kyri, Hancock, Gerald E., Kunz, Arthur, Hegen, Martin, Zhou, Xiaochuan X., Sheppard, Barbara J., Lamothe, Jennifer, Li, Evelyn, Ma, Hak-Ling, Hamann, Philip R., Damle, Nitin K., Collins, Mary

“…We report the development of a mouse B cell-depleting immunoconjugate (anti-CD22 monoclonal antibody [mAb] conjugated to calicheamicin) and its in vivo use to…”
Get full text

Preparation and characterization of monoclonal antibody conjugates of the calicheamicins : a novel and potent family of antitumor antibiotics by HINMAN, L. M, HAMANN, P. R, WALLACE, R, MENENDEZ, A. T, DURR, F. E, UPESLACIS, J

“…The calicheamicin family of antitumor antibiotics are capable of producing double-stranded DNA breaks at sub-picomolar concentrations. Their potency suggested…”
Get full text

Synthesis and structure of the platelet aggregation factor thromboxane A2 by BHAGWAT, S. S, HAMANN, P. R, STILL, W. C, BUNTING, S, FITZPATRICK, F. A

“…In 1975, Hamberg et al. reported evidence for the existence of an unstable platelet-aggregating factor which they named thromboxane A2 (TXA2) and for which…”
Get full text